Just announced: GSK cancer vaccine disappoints in melanoma trial.
This is great for ONCS.
Sentiment: Strong Buy
Well that's 2 gone ,the being clsn
Get ready for a nice ride.
Absolutely the reason we are up today. Our biggest competiton just folded.
VICL out, now the GSK entry - ONCS with the best preliminary efficacy indications of any (up to 45% response rate) and we sit with a $40 M MC.....betting not for long though.